$6.69
3.46% yesterday
Nasdaq, Aug 25, 10:01 pm CET
ISIN
US8808811074
Symbol
TERN

Terns Pharmaceuticals Inc Stock price

$6.69
+0.64 10.58% 1M
+2.98 80.32% 6M
+1.15 20.76% YTD
-1.59 19.20% 1Y
+2.28 51.70% 3Y
-10.31 60.65% 5Y
-10.31 60.65% 10Y
-10.31 60.65% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-0.24 3.46%
ISIN
US8808811074
Symbol
TERN
Industry

Key metrics

Basic
Market capitalization
$606.5m
Enterprise Value
$291.0m
Net debt
positive
Cash
$315.5m
Shares outstanding
87.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
95.0%
Return on Equity
-25.7%
ROCE
-34.4%
ROIC
-6,388.6%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-105.1m | $-118.3m
EBIT
$-105.8m | $-120.6m
Net Income
$-91.8m | $-99.1m
Free Cash Flow
$-74.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
2.8% | -17.1%
EBIT
2.7% | -18.3%
Net Income
4.5% | -11.5%
Free Cash Flow
6.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.0
FCF per Share
$-0.8
Short interest
7.7%
Employees
59
Rev per Employee
$0.0
Show more

Is Terns Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Terns Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Terns Pharmaceuticals Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Terns Pharmaceuticals Inc forecast:

Buy
86%
Hold
14%

Financial data from Terns Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 33 33
14% 14%
-
- Research and Development Expense 72 72
4% 4%
-
-105 -105
3% 3%
-
- Depreciation and Amortization 0.69 0.69
11% 11%
-
EBIT (Operating Income) EBIT -106 -106
3% 3%
-
Net Profit -92 -92
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Terns Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Terns Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
4 days ago
FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced it will host an investor educational webinar on TERN-701 in advance of the data release exp...
Neutral
The Motley Fool
20 days ago
Terns (TERN) Q2 Net Loss Narrows 16%
Neutral
GlobeNewsWire
20 days ago
Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25
More Terns Pharmaceuticals Inc News

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Head office United States
CEO Amy Burroughs
Employees 59
Founded 2017
Website ternspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today